Adlai Nortye Ltd. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ANL Nasdaq 2834 www.adlainortye.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Adlai Nortye Ltd.

3 US Penny Stocks With Market Caps Over $80M To Watch - Jan 1st, 2025 12:09 am
Adlai Nortye Ltd. (NASDAQ:ANL) stock most popular amongst retail investors who own 42%, while employee share scheme hold 29% - Sep 5th, 2024 1:44 pm
Adlai Nortye Reports Unaudited First Half 2024 Financial Results and Highlights Recent Operational Progress - Aug 8th, 2024 12:30 pm
Adlai Nortye Appoints Roger Sawhney, M.D. to Its Board of Directors - Aug 8th, 2024 12:00 pm
Adlai Nortye Ltd. to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy (dCRT) at ASCO 2024 - May 24th, 2024 1:03 am
Adlai Nortye Announces First Patient Dosed in Randomized Phase II Clinical Trial of Palupiprant (AN0025) for the Treatment of Locally Advanced Rectal Cancer with Radiation Therapy - May 22nd, 2024 12:00 pm
Adlai Nortye Ltd.'s (NASDAQ:ANL) largest shareholders are retail investors with 59% ownership, insiders own 16% - Mar 29th, 2024 12:40 pm
Adlai Nortye Announces Appointment of Dr. Archie Tse as the Head of Research & Development - Mar 29th, 2024 10:00 am